- Home
- IBG vs EVAX Comparison
IBG vs EVAX Comparison
Compare IBG & EVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IBG
- EVAX
- Stock Information
- Founded
- IBG 2018
- EVAX 2008
- Country
- IBG Australia
- EVAX Denmark
- Employees
- IBG N/A
- EVAX N/A
- Industry
- IBG Beverages (Production/Distribution)
- EVAX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- IBG Consumer Staples
- EVAX Health Care
- Exchange
- IBG Nasdaq
- EVAX Nasdaq
- Market Cap
- IBG 9.6M
- EVAX 8.7M
- IPO Year
- IBG 2024
- EVAX 2021
- Fundamental
- Price
- IBG $1.14
- EVAX $1.06
- Analyst Decision
- IBG Strong Buy
- EVAX Strong Buy
- Analyst Count
- IBG 1
- EVAX 2
- Target Price
- IBG N/A
- EVAX $11.00
- AVG Volume (30 Days)
- IBG 220.7K
- EVAX 808.1K
- Earning Date
- IBG 02-15-2025
- EVAX 10-31-2024
- Dividend Yield
- IBG N/A
- EVAX N/A
- EPS Growth
- IBG N/A
- EVAX N/A
- EPS
- IBG N/A
- EVAX N/A
- Revenue
- IBG $3,147,763.00
- EVAX $3,295,000.00
- Revenue This Year
- IBG N/A
- EVAX $4,845.21
- Revenue Next Year
- IBG N/A
- EVAX $30.30
- P/E Ratio
- IBG N/A
- EVAX N/A
- Revenue Growth
- IBG N/A
- EVAX N/A
- 52 Week Low
- IBG $0.60
- EVAX $0.84
- 52 Week High
- IBG $3.35
- EVAX $13.61
- Technical
- Relative Strength Index (RSI)
- IBG N/A
- EVAX 37.33
- Support Level
- IBG N/A
- EVAX $0.84
- Resistance Level
- IBG N/A
- EVAX $0.96
- Average True Range (ATR)
- IBG 0.00
- EVAX 0.15
- MACD
- IBG 0.00
- EVAX 0.02
- Stochastic Oscillator
- IBG 0.00
- EVAX 38.80
About IBG Innovation Beverage Group Limited Ordinary Shares
Innovation Beverage Group Ltd is a developer, manufacturer, marketer, exporter and retailer of a growing beverage portfolio of 60 formulations across 13 alcoholic and non-alcoholic brands. The company's focus is on premium and super premium brands.
About EVAX Evaxion Biotech A/S
Evaxion Biotech AS is a clinical-stage biotech company that aspires to the exploration of artificial intelligence, or AI, to develop immunotherapies with improved efficacy when compared to currently marketed products for patients with unmet medical needs. Its pipeline programs are derived from its proprietary AI platforms, PIONEER, EDEN, RAVEN, and ObsERV. The company is utilizing these AI platforms to build a drug development pipeline. Its product candidates are; EVX-01 and EVX-02, for the treatment of various cancers, and the third candidate is cancer immunotherapy, EVX-03, for the treatment of various cancers including non-small-cell-lung-cancer, or NSCLC, is in pre-clinical development.